Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: The gut microbiome plays a critical role in modulating the therapeutic effect of immune checkpoint inhibitors (ICIs). Proton pump inhibitors (PPIs) are commonly used in cancer patients and may affect the gut microbiome by altering gut pH. Objective: To evaluate if concurrent use of PPI is associated with overall survival (OS) and progression-free survival (PFS) in patients with stage IV non–small-cell lung cancer (NSCLC), melanoma, renal cell carcinoma, transitional cell carcinoma, or head and neck squamous cell carcinoma. Methods: This was a single-center retrospective cohort study of advanced cancer adult patients who received nivolumab or pembrolizumab between September 1, 2014, and August 31, 2019. Concomitant PPI exposure was defined as PPI use 0 to 30 days before or after initiation of ICIs. Treatment outcome was OS and PFS. Results: A total of 233 patients were included in our study. Concomitant PPI use was not significantly associated with OS (hazard ratio [HR] = 1.22; 95% CI = 0.80-1.86) or PFS (HR = 1.05; 95% CI = 0.76-1.45) in patients with ICI use. The effect estimates were robust after adjusting for covariates in multivariate analysis and in patients with NSCLC. Conclusion and Relevance: Concomitant PPI use was not associated with the effectiveness of nivolumab or pembrolizumab. Certain predictors of survival outcomes related to PPI use in patients receiving immunotherapy, such as the time window and indication of PPI exposure and autoimmune disorders, should be explored in the future to better carve out the impact of PPI on the effectiveness of ICI use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy103 · Cited by 908
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895
Pinato, D. J., Howlett, S., Ottaviani, D., Urus, H., Patel, A., Mineo, T., Brock, C., Power, D., Hatcher, O., Falconer, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2785 · Cited by 626 · cited 1×
“(Active cancer was defined as any cancer diagnosed or treated within 1 year before and 1 year after initiation of nivolumab or pembrolizumab; localized basal cell carcinoma, squamous cell carcinoma, or prostate cancer was not counted as active cancer); (3) patients with a history of immunotherapy prior to initiating n…”
BackgroundRicciuti, B., Dahlberg, S. E., Adeni, A., Sholl, L. M., Nishino, M., & Awad, M. M. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00189 · Cited by 333 · cited 1×
“Age, years, n (%) Median, range 64 (25-91) 64 (26-91) 64 (25-87) 64 (30-89) 63.”
Chalabi, M., Cardona, A., Nagarkar, D. R., Dhawahir Scala, A., Gandara, D. R., Rittmeyer, A., Albert, M. L., Powles, T., Kok, M., & Herrera, F. G. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.006 · Cited by 294
Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001361 · Cited by 275
Tinsley, N., Zhou, C., Tan, G., Rack, S., Lorigan, P., Blackhall, F., Krebs, M., Carter, L., Thistlethwaite, F., Graham, D., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0160 · Cited by 201
Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors
Hojo, M., Asahara, T., Nagahara, A., Takeda, T., Matsumoto, K., Ueyama, H., Matsumoto, K., Asaoka, D., Takahashi, T., Nomoto, K., et al. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5122-4 · Cited by 114
Cited by
Lopes, S., Pabst, L., Dory, A., Klotz, M., Gourieux, B., Michel, B., & Mascaux, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070076 · Cited by 75
“Peng (44) 2022 233 America 130 (55,8) 64 186/47 Multiple Nivolumab, pembrolizumab, and ipilimumab First, second, or beyond Monothera association”
BackgroundGamrath, L., Pedersen, T. B., Møller, M. V., Volmer, L. M., Holst-Christensen, L., Vestermark, L. W., & Donskov, F. (2025) · Current Oncology Reports · doi:10.1007/s11912-024-01622-6 · Cited by 30
“For instance, a study by Peng et al. on 233 cancer patients found no difference between PPI users and non-PPI users [65], and the same was true for Hamada´s study on 69 patients with NSCLC [62].”
Cantarelli, L., Gutiérrez Nicolás, F., García Gil, S., Morales Barrios, J. A., Oramas Rodriguez, J., & Nazco Casariego, G. J. (2024) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000494 · Cited by 4
“23 – 26 Therefore, the main purpose and objective of the following study was to evaluate the correlation between the use of PPIs and the effectiveness, in terms of overall survival (OS) and progression-free survival (PFS), of ICI therapy in patients with advanced stage IV disease in a real clinical…”
Background
Metadata
- Authors
- Peng, K., Chen, K., Teply, B. A., Yee, G. C., Farazi, P. A., & Lyden, E. R.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2021-07-20
- Volume
- 56
- Issue
- 4
- Pages
- 377-386
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W3166848715
- Cited by
- 40
- References
- 11
- FWCI
- 2.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. https://app.cochat.ai/papers/10.1177/10600280211033938
- The paper
- Peng, K., Chen, K., Teply, B. A., Yee, G. C., Farazi, P. A., & Lyden, E. R. (2022). Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280211033938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.